Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Mangoceuticals (MGRX) Income from Non-Controlling Interests (2023 - 2025)

Mangoceuticals' Income from Non-Controlling Interests history spans 3 years, with the latest figure at $197.0 for Q4 2025.

  • On a quarterly basis, Income from Non-Controlling Interests rose 180.74% to $197.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$461.0, a 57.35% increase, with the full-year FY2025 number at -$461.0, up 57.35% from a year prior.
  • Income from Non-Controlling Interests hit $197.0 in Q4 2025 for Mangoceuticals, up from -$558.0 in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for MGRX hit a ceiling of $197.0 in Q4 2025 and a floor of -$1.8 million in Q3 2023.
  • Historically, Income from Non-Controlling Interests has averaged -$200111.3 across 3 years, with a median of -$244.0 in 2024.
  • The widest YoY moves for Income from Non-Controlling Interests: up 180.74% in 2025, down 172.22% in 2025.
  • Tracing MGRX's Income from Non-Controlling Interests over 3 years: stood at -$1.8 million in 2023, then surged by 99.99% to -$244.0 in 2024, then soared by 180.74% to $197.0 in 2025.
  • Business Quant data shows Income from Non-Controlling Interests for MGRX at $197.0 in Q4 2025, -$558.0 in Q3 2025, and -$2.0 in Q2 2025.